Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)

v3.24.1.u1
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
Sep. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
Mar. 31, 2024
USD ($)
segment
shares
Dec. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Sep. 30, 2022
USD ($)
Mar. 31, 2024
USD ($)
shares
Mar. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
shares
Number of Operating Segments | segment       2            
Proceeds from sale of Eminence               $ 0 $ 17,824  
Revenues, net       $ 303,428   $ 294,146   852,961 835,382  
Gain on sale of Eminence               0 11,682  
Gain (loss) on equity method investment       (1,747)       (5,950)    
Investment in Wilson Wolf                 232,000  
Positions eliminated during the period as a percentage         4.00%          
Current liabilities attributable to disposal group held for sale       $ 689       689   $ 0
Impairment of Long-Lived Assets to be Disposed of               $ 6,038 $ 0  
Common stock, shares authorized (in shares) | shares       400,000,000       400,000,000   400,000,000
Eminence Biotechnology                    
Proceeds from sale of Eminence   $ 17,800                
Protein Sciences                    
Goodwill attributable to disposal group held for sale         $ 1,400          
Current liabilities attributable to disposal group held for sale       $ 700       $ 700    
Pre-tax restructuring charges               220   $ 1,700
Protein Sciences | Current Assets, Held For Sale                    
Inventory attributable to disposal group       11,200       11,200    
Property, plant and equipment attributable to disposal group held for sale       5,600       5,600    
Intangible assets, excluding goodwill, attributable to disposal group held for sale       14,300       14,300    
Protein Sciences | Eminence Biotechnology                    
Revenues, net             $ 2,000      
Wilson Wolf Corporation                    
Investment percentage 19.90%         19.90%     19.90%  
Gain (loss) on equity method investment       (1,700)       (6,000)    
Investment amount       $ 248,000       $ 248,000   256,000
Payments to Acquire Investments $ 232,000   $ 25,000              
Forward Contract, Milestone, Multiple for Total Expected Payments       4.4       4.4    
Wilson Wolf Corporation | First Part of Forward Contract                    
Forward Contract, Milestone, Annual Revenue Required       $ 92,000       $ 92,000    
Forward Contract, Milestone, Annual EBITDA       55,000       55,000    
Wilson Wolf Corporation | Second Part of Forward Contract                    
Forward Contract, Milestone, Annual Revenue Required       226,000       226,000    
Forward Contract, Milestone, Annual EBITDA       136,000       136,000    
Forward Contract, Additional Investment       $ 1,000,000       1,000,000    
Selling, General and Administrative Expenses | Protein Sciences                    
Asset Impairment Charges               $ 6,000    
QT Holdings Corporation | Protein Sciences                    
Pre-tax restructuring charges                   $ 2,200
Eminence Biotechnology | Nonoperating Income (Expense)                    
Gain on sale of Eminence             $ 11,700